Mod GRF 1-29

Overview

Mod GRF 1-29, commonly referred to as CJC-1295 without DAC, is a synthetic peptide analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). The native GHRH(1-29) fragment, also known as sermorelin, retains full biological activity at the GHRH receptor but suffers from extremely rapid enzymatic degradation, with a plasma half-life of only 5-7 minutes.

Mod GRF 1-29 addresses this limitation through four strategic amino acid substitutions at positions 2, 8, 15, and 27. These modifications confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage and general proteolytic degradation, extending the effective half-life to approximately 30 minutes. Crucially, unlike CJC-1295 DAC, Mod GRF 1-29 lacks the Drug Affinity Complex and does not bind to serum albumin, resulting in a shorter but more physiological duration of action.

This shorter half-life is considered advantageous by some researchers because it produces discrete GH pulses that more closely resemble the natural pulsatile secretion pattern. This contrasts with CJC-1295 DAC, which produces prolonged GH elevation over days. Mod GRF 1-29 is frequently studied in combination with GH secretagogues such as Ipamorelin or GHRP-6 to exploit the synergy between the GHRH and ghrelin receptor pathways.

Mechanism of Action

Mod GRF 1-29 acts as a selective agonist of the GHRH receptor (GHRHR), mimicking the action of endogenous GHRH on pituitary somatotroph cells.

GHRH Receptor Signaling

Upon binding to the GHRHR on somatotroph cells of the anterior pituitary, Mod GRF 1-29 activates the stimulatory G-protein (Gs), which in turn activates adenylyl cyclase. This leads to increased intracellular cyclic AMP (cAMP) production and activation of protein kinase A (PKA). PKA phosphorylates L-type voltage-gated calcium channels, promoting calcium influx that triggers GH vesicle exocytosis. Additionally, PKA activates the transcription factor CREB, which promotes GH gene transcription for sustained GH production.

Pulsatile GH Release

Because Mod GRF 1-29 has a half-life of approximately 30 minutes (compared to 6-8 days for CJC-1295 DAC), it produces acute GH pulses rather than sustained elevation. Each administration generates a single GH pulse peaking at approximately 30 minutes and returning to baseline within 2-3 hours. This pulsatile pattern preserves GH receptor sensitivity and maintains the natural negative feedback through somatostatin and IGF-1.

Synergistic Combination Pharmacology

The cAMP pathway activated by Mod GRF 1-29 is biochemically distinct from the IP3-calcium pathway activated by GH secretagogues like Ipamorelin. When both pathways are simultaneously activated, the result is a synergistic rather than merely additive GH response. Research has shown that the combination can amplify GH pulse amplitude by 3-5 fold compared to either agent alone.

Research Summary

Development of Modified GHRH Analogs

The original characterization of GHRH(1-29) as the minimal fully active fragment was established by Ling et al. (1984) in Biochemical and Biophysical Research Communications. The four amino acid substitutions used in Mod GRF 1-29 were developed based on structure-activity relationship studies by multiple groups. The D-Ala2 substitution, first described by Frohman et al. (1989) in Journal of Clinical Investigation, was shown to prevent DPP-IV cleavage, the primary route of GHRH inactivation in plasma.

Pharmacokinetic Comparisons

Research comparing Mod GRF 1-29 to native GHRH(1-29) (sermorelin) demonstrated a 4-5 fold extension of biological half-life. Whereas sermorelin produces a GH pulse lasting approximately 15-20 minutes, Mod GRF 1-29 produces a pulse lasting 60-90 minutes. This was documented in comparative pharmacokinetic studies by ConjuChem during the development of the CJC-1295 platform (Alba et al., 2006, Journal of Clinical Endocrinology & Metabolism).

GHRH-GHRP Synergy Studies

Veldhuis et al. (2005), publishing in the Journal of Clinical Endocrinology & Metabolism, systematically characterized the synergistic interaction between GHRH analogs and GH secretagogues. Using deconvolution analysis of GH secretory profiles, they demonstrated that combined administration amplified GH pulse mass by approximately 5-fold compared to GHRH alone and 3-fold compared to GHRP alone. This synergy was most pronounced in older subjects with declining GH secretion.

Sermorelin Clinical Precedent

While direct clinical trial data on Mod GRF 1-29 specifically is limited, extensive clinical data exists for its parent compound sermorelin (Geref, approved by the FDA in 1997 for GH deficiency). Walker et al. (1990) in Journal of Clinical Endocrinology & Metabolism demonstrated that chronic sermorelin administration effectively stimulated linear growth in GH-deficient children, validating the therapeutic potential of GHRH receptor agonism. Mod GRF 1-29 is expected to exhibit similar pharmacodynamics with improved metabolic stability.

Dosing in Published Research

Mod GRF 1-29 is a modified fragment of growth-hormone-releasing hormone, closely related to (and often sold as) CJC-1295 without DAC. Unlike the DAC-modified version, this short-acting form has not been the subject of dedicated published human clinical trials, so no controlled study has established a dose for it. Figures that circulate for Mod GRF 1-29 in forums and vendor material are not derived from peer-reviewed human research and are therefore not reported here.

Safety and Side Effects

Modified GRF 1-29 has not been characterized by adequate human safety trials. As a short-acting growth-hormone-releasing hormone analog it raises growth hormone in a pulse-like manner, and its expected adverse effects are those of the growth hormone secretagogue class: fluid retention, transient changes in insulin sensitivity and blood glucose, headache, flushing, and injection-site reactions. Because its half-life is short, the elevation of growth hormone and IGF-1 is less sustained than with the DAC-modified version, but long-term human safety data are nonetheless absent. Unregulated material is of uncertain identity and purity.

Current Research Status

Modified GRF 1-29 is not approved by the FDA or any major regulatory agency for any use. It is closely related to CJC-1295 and is prohibited in sport by the World Anti-Doping Agency as a growth hormone secretagogue. It is sold only as a research chemical and should be regarded as investigational.

Frequently Asked Questions